AGP Executive Report
Last update: 20 hours agoCancer Research & Clinical Trials: Salubris Biotherapeutics shared updated Phase 1/2 results for JK06, a 5T4-targeted antibody drug conjugate, presented at the 2026 ASCO meeting in Chicago—showing a 50% overall response rate in squamous NSCLC at the 4.5 mg/kg dose, with a 35% ORR and 94% disease control rate across response-evaluable patients, plus a favorable safety profile. Long COVID in Kids: A Children’s National/NIH PECOS study published in Pediatric Research found that about two-thirds of children and teens with confirmed SARS-CoV-2 reported at least one post-infection symptom at 12 months, with 20 symptoms appearing more often than in uninfected controls through a year. Maternal Mental Health Policy: Maryland signed perinatal behavioral health coverage into law, a milestone aimed at improving support for maternal mental health. Hospital Safety & Access: The 4th Circuit agreed to rehear challenges to Maryland and West Virginia 340B contract pharmacy laws, a fight that could affect how safety-net hospitals access discounted medications. Public Health & Environment: Advocates warned that garbage incinerators are failing to cut “forever chemical” PFAS air pollution, including concerns about facilities in the region. Local Health Alerts: Baltimore saw two overnight shootings in early Saturday hours, leaving one man dead and others injured, underscoring ongoing community health and safety needs.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
Pseudo-journalism: Pink-slime
